Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial

Atrial Fibrillation

Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial Fibrillation

Circ Cardiovasc Qual Outcomes

Bergmark BA, Park JG, Hamershock RA, Melloni GEM, De Caterina R, Antman EM, Ruff CT, Rutman H, Mercuri MF, Lanz HJ, Braunwald E, Giugliano RP

doi: 10.1161/CIRCOUTCOMES.123.010561

Atrial Fibrillation

Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial

JAMA Cardiol

Alexander JH, Lydon EJ, Piccini JP, Viethen T, Oldgren J, Goodman SG, Steffel J, Russo AM, van Gelder IC, Ferdinand KC, Lopes RD, Mundl H, Benczur B, Gómez-Doblas JJ, Glikson M, Goudev A, Grove EL, Halvorsen S, Kiviniemi T, Martin AC, Sandhu RK, Vinereanu D, Rockhold FW, Caso V, Coppolecchia R, Patel MR

doi: 10.1001/jamacardio.2025.0277

Heart Failure

Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial

JAMA Cardiol

Matsumoto S, Henderson AD, Jhund PS, Bauersachs J, Chioncel O, Claggett BL, Comin-Colet J, Desai AS, Filippatos G, Lam CSP, Pitt B, Scheerer MF, Lay-Flurrie J, Amarante F, Brinker M, Schou M, Senni M, Shah SJ, Voors AA, Zannad F, Zieroth S, Vaduganathan M, Solomon SD, McMurray JJV

doi: 10.1001/jamacardio.2025.0848

Further Publications

Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial

JAMA Cardiol

Benziger CP, Stebbins A, Wruck LM, Effron MB, Marquis-Gravel G, Farrehi PM, Girotra S, Gupta K, Kripalani S, Munoz D, Polonsky TS, Sharlow A, Whittle J, Harrington RA, Rothman RL, Hernandez AF, Jones WS

doi: 10.1001/jamacardio.2024.1712

Atrial Fibrillation

Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study

Int J Cardiol

Kirchhof P, Bakhai A, de Asmundis C, de Groot JR, Deharo JC, Kelly P, Lopez-de-Sa E, Monteiro P, Fronk EM, Lamparter M, Laeis P, Smolnik R, Steffel J, Waltenberger J, Weiss TW, De Caterina R

doi: 10.1016/j.ijcard.2024.132118

Further Publications

Contribution of Clinical Trial Event Data by Data Source: A Prespecified Analysis of the ADAPTABLE Randomized Clinical Trial

JAMA Cardiol

Rymer JA, Mulder H, Wruck LM, Muñoz D, Kripalani S, Effron MB, Gupta K, Handberg E, Jain S, Girotra S, Whittle J, Hess R, Benziger CP, Knowlton KU, Curtis LH, Roe MT, Hammill BG, Rothman RL, Harrington R, Hernandez A, Jones WS

doi: 10.1001/jamacardio.2024.2019

Atrial FibrillationHeart, Artery and Coronary Diseases

Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials

J Am Coll Cardiol

Rashedi S, Keykhaei M, Sato A, Steg PG, Piazza G, Eikelboom JW, Lopes RD, Bonaca MP, Yasuda S, Ogawa H, Shizuta S, Kimura T, Okumura Y, Andreotti F, Bertoletti L, Stone GW, Mehran R, Cohen DJ, Lip GYH, Bikdeli B

doi: 10.1016/j.jacc.2024.12.030

Atrial Fibrillation

Design and Rationale of a Pragmatic Randomized Clinical Trial of Early Dronedarone versus Usual Care to Change and Improve Outcomes in Persons with First-Detected Atrial Fibrillation - The CHANGE AFIB Study

Am Heart J

Pokorney SD, Nemeth H, Chiswell K, Albert C, Allyn N, Blanco R, Butler J, Calkins H, Elkind MSV, Fonarow GC, Fontaine JM, Frankel DS, Fermann GJ, Gale R, Kalscheur M, Kirchhof P, Koren A, Miller JB, Rashkin J, Russo AM, Rutan C, Steinberg B, Piccini JP

doi: 10.1016/j.ahj.2024.10.001

Atrial FibrillationHeart Failure

Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AF

J Am Coll Cardiol

Haller PM, Jarolim P, Palazzolo MG, Bellavia A, Antman EM, Eikelboom J, Granger CB, Harrington J, Healey JS, Hijazi Z, Patel MR, Patel SM, Ruff CT, Wallentin L, Braunwald E, Giugliano RP, Morrow DA

doi: 10.1016/j.jacc.2024.07.023

Related content

Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial Fibrillation

Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial

Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial

Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial

Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study

Contribution of Clinical Trial Event Data by Data Source: A Prespecified Analysis of the ADAPTABLE Randomized Clinical Trial

Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials

Design and Rationale of a Pragmatic Randomized Clinical Trial of Early Dronedarone versus Usual Care to Change and Improve Outcomes in Persons with First-Detected Atrial Fibrillation - The CHANGE AFIB Study

Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AF